Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CL stock price vs NTRA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NTRA's multiple
Needs NTRA P/E.
Implied fair value · at CL's multiple
Needs Annual EPS is negative, CL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
COLGATE-PALMOLIVE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NATERA, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CL vs PG
JOHNSON & JOHNSON
CL vs JNJ
CHURCH & DWIGHT CO INC /DE/
CL vs CHD
KIMBERLY CLARK CORP
CL vs KMB
EDGEWELL PERSONAL CARE Co
CL vs EPC
UNILEVER PLC
CL vs UL
ILLUMINA, INC.
CL vs ILMN
EXACT SCIENCES CORP
CL vs EXAS
AMGEN INC
CL vs AMGN
VERTEX PHARMACEUTICALS INC / MA
CL vs VRTX
REGENERON PHARMACEUTICALS, INC.
CL vs REGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CL's premium operating quality and strong cash-generation profile deserve to remain valued closer to its historical range than to NTRA's sales multiple, then hold or accumulate CL because the relative valuation output is likely overstated by NTRA mismatch.
The comparison shows an extreme valuation disconnect: the model-implied price of $511.95 suggests 448.9% upside from CL's current price of $93.27. However, that implied level is far above both the historical band of $83.94-$102.60 and the DCF range of $23.41-$31.67, indicating the P/S-based output is likely distorted by NTRA setup and NTRA's much higher sales multiple.
Supporting Metrics
